BRCA2 and neoplasm: Two patients received therapies following the recommendations of the local molecular tumor board, as mutations with only low or no levels of evidence for actionability were detected (BRCA2 S497L in pancreatic adenocarcinoma; ERBB3 G284R in CCC).